A detailed history of Wells Fargo & Company transactions in Enochian Biosciences Inc stock. As of the latest transaction made, Wells Fargo & Company holds 17,739 shares of ENOB stock, worth $81,599. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,739
Previous 294 5933.67%
Holding current value
$81,599
Previous $1,000 8000.0%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
N/A
17,445 Added 5933.67%
17,739 $81,000
Q1 2024

May 10, 2024

BUY
N/A
7 Added 2.44%
294 $1,000
Q4 2023

Feb 09, 2024

BUY
$4.3 - $4.7 $313 - $343
73 Added 34.11%
287 $1,000
Q3 2023

Nov 13, 2023

SELL
$0.0 - $4.46 $0 - $1,217
-273 Reduced 56.06%
214 $0
Q2 2023

Aug 15, 2023

SELL
$0.4 - $1.3 $1,194 - $3,881
-2,986 Reduced 85.98%
487 $0
Q1 2023

May 12, 2023

BUY
$0.91 - $1.31 $3,160 - $4,549
3,473 New
3,473 $3,000
Q3 2022

Nov 14, 2022

SELL
$1.7 - $2.86 $353 - $594
-208 Reduced 94.55%
12 $0
Q2 2022

Aug 12, 2022

BUY
$1.93 - $8.73 $243 - $1,099
126 Added 134.04%
220 $0
Q1 2022

May 16, 2022

BUY
$4.42 - $9.0 $4 - $9
1 Added 1.08%
94 $1,000
Q4 2021

Feb 14, 2022

BUY
$6.71 - $12.55 $6 - $12
1 Added 1.09%
93 $1,000
Q3 2021

Nov 15, 2021

SELL
$4.56 - $7.88 $13 - $23
-3 Reduced 3.16%
92 $1,000
Q2 2021

Aug 16, 2021

SELL
$2.94 - $6.79 $13,812 - $31,899
-4,698 Reduced 98.02%
95 $0
Q1 2021

May 13, 2021

SELL
$3.02 - $4.51 $52,418 - $78,280
-17,357 Reduced 78.36%
4,793 $17,000
Q4 2020

Feb 09, 2021

SELL
$2.82 - $3.55 $48,484 - $61,035
-17,193 Reduced 43.7%
22,150 $65,000
Q3 2020

Nov 05, 2020

SELL
$3.42 - $4.55 $8,515 - $11,329
-2,490 Reduced 5.95%
39,343 $141,000
Q2 2020

Aug 13, 2020

BUY
$2.78 - $6.06 $25,478 - $55,539
9,165 Added 28.05%
41,833 $176,000
Q1 2020

May 14, 2020

BUY
$2.08 - $5.41 $67,949 - $176,733
32,668 New
32,668 $98,000

Others Institutions Holding ENOB

About Enochian Biosciences Inc


  • Ticker ENOB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,950,000
  • Market Cap $244M
  • Description
  • Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for au...
More about ENOB
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.